Elite Pharmaceuticals’ Generic Adderall® Approved in Israel
Company Announcements

Elite Pharmaceuticals’ Generic Adderall® Approved in Israel

Elite Pharmaceuticals ( (ELTP) ) has shared an announcement.

Elite Pharmaceuticals has received approval from the Israeli Ministry of Health for its generic version of Adderall®, designed to treat ADHD and narcolepsy. The company will partner with Dexcel Pharma, its exclusive distributor for the Israeli market, to manufacture and package the product under Dexcel’s brand. Dexcel will handle sales, marketing, and distribution and share profits with Elite under specific conditions. The launch date for Elite’s generic Adderall® will depend on various factors, including licensee orders and manufacturing schedules.

For detailed information about ELTP stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskElite Pharmaceuticals Launches Generic Pain Medication
TipRanks Auto-Generated NewsdeskElite Pharmaceuticals Unveils Generic Methotrexate Tablets
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App